Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology

Thomas M. Gorter, Dirk J. van Veldhuisen, Johann Bauersachs, Barry A. Borlaug, Jelena Celutkiene, Andrew J.S. Coats, Marisa G. Crespo-Leiro, Marco Guazzi, Veli Pekka Harjola, Stephane Heymans, Loreena Hill, Mitja Lainscak, Carolyn S.P. Lam, Lars H. Lund, Alexander R. Lyon, Alexandre Mebazaa, Christian Mueller, Walter J. Paulus, Burkert Pieske, Massimo F. PiepoliFrank Ruschitzka, Frans H. Rutten, Petar M. Seferovic, Scott D. Solomon, Sanjiv J. Shah, Filippos Triposkiadis, Rolf Wachter, Carsten Tschöpe, Rudolf A. de Boer

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.

Original languageEnglish
Pages (from-to)16-37
Number of pages22
JournalEuropean Journal of Heart Failure
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Heart Failure
Therapeutics
Morbidity
Mortality

Keywords

  • Biomarkers
  • Heart failure
  • Heart failure with preserved ejection fraction
  • Pulmonary hypertension
  • Right ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Right heart dysfunction and failure in heart failure with preserved ejection fraction : mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. / Gorter, Thomas M.; van Veldhuisen, Dirk J.; Bauersachs, Johann; Borlaug, Barry A.; Celutkiene, Jelena; Coats, Andrew J.S.; Crespo-Leiro, Marisa G.; Guazzi, Marco; Harjola, Veli Pekka; Heymans, Stephane; Hill, Loreena; Lainscak, Mitja; Lam, Carolyn S.P.; Lund, Lars H.; Lyon, Alexander R.; Mebazaa, Alexandre; Mueller, Christian; Paulus, Walter J.; Pieske, Burkert; Piepoli, Massimo F.; Ruschitzka, Frank; Rutten, Frans H.; Seferovic, Petar M.; Solomon, Scott D.; Shah, Sanjiv J.; Triposkiadis, Filippos; Wachter, Rolf; Tschöpe, Carsten; de Boer, Rudolf A.

In: European Journal of Heart Failure, Vol. 20, No. 1, 01.01.2018, p. 16-37.

Research output: Contribution to journalArticle

Gorter, TM, van Veldhuisen, DJ, Bauersachs, J, Borlaug, BA, Celutkiene, J, Coats, AJS, Crespo-Leiro, MG, Guazzi, M, Harjola, VP, Heymans, S, Hill, L, Lainscak, M, Lam, CSP, Lund, LH, Lyon, AR, Mebazaa, A, Mueller, C, Paulus, WJ, Pieske, B, Piepoli, MF, Ruschitzka, F, Rutten, FH, Seferovic, PM, Solomon, SD, Shah, SJ, Triposkiadis, F, Wachter, R, Tschöpe, C & de Boer, RA 2018, 'Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology', European Journal of Heart Failure, vol. 20, no. 1, pp. 16-37. https://doi.org/10.1002/ejhf.1029
Gorter, Thomas M. ; van Veldhuisen, Dirk J. ; Bauersachs, Johann ; Borlaug, Barry A. ; Celutkiene, Jelena ; Coats, Andrew J.S. ; Crespo-Leiro, Marisa G. ; Guazzi, Marco ; Harjola, Veli Pekka ; Heymans, Stephane ; Hill, Loreena ; Lainscak, Mitja ; Lam, Carolyn S.P. ; Lund, Lars H. ; Lyon, Alexander R. ; Mebazaa, Alexandre ; Mueller, Christian ; Paulus, Walter J. ; Pieske, Burkert ; Piepoli, Massimo F. ; Ruschitzka, Frank ; Rutten, Frans H. ; Seferovic, Petar M. ; Solomon, Scott D. ; Shah, Sanjiv J. ; Triposkiadis, Filippos ; Wachter, Rolf ; Tschöpe, Carsten ; de Boer, Rudolf A. / Right heart dysfunction and failure in heart failure with preserved ejection fraction : mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. In: European Journal of Heart Failure. 2018 ; Vol. 20, No. 1. pp. 16-37.
@article{5c089f2c0dbc4995b6e4c74a6d121cca,
title = "Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology",
abstract = "There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.",
keywords = "Biomarkers, Heart failure, Heart failure with preserved ejection fraction, Pulmonary hypertension, Right ventricular function",
author = "Gorter, {Thomas M.} and {van Veldhuisen}, {Dirk J.} and Johann Bauersachs and Borlaug, {Barry A.} and Jelena Celutkiene and Coats, {Andrew J.S.} and Crespo-Leiro, {Marisa G.} and Marco Guazzi and Harjola, {Veli Pekka} and Stephane Heymans and Loreena Hill and Mitja Lainscak and Lam, {Carolyn S.P.} and Lund, {Lars H.} and Lyon, {Alexander R.} and Alexandre Mebazaa and Christian Mueller and Paulus, {Walter J.} and Burkert Pieske and Piepoli, {Massimo F.} and Frank Ruschitzka and Rutten, {Frans H.} and Seferovic, {Petar M.} and Solomon, {Scott D.} and Shah, {Sanjiv J.} and Filippos Triposkiadis and Rolf Wachter and Carsten Tsch{\"o}pe and {de Boer}, {Rudolf A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ejhf.1029",
language = "English",
volume = "20",
pages = "16--37",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "1",

}

TY - JOUR

T1 - Right heart dysfunction and failure in heart failure with preserved ejection fraction

T2 - mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology

AU - Gorter, Thomas M.

AU - van Veldhuisen, Dirk J.

AU - Bauersachs, Johann

AU - Borlaug, Barry A.

AU - Celutkiene, Jelena

AU - Coats, Andrew J.S.

AU - Crespo-Leiro, Marisa G.

AU - Guazzi, Marco

AU - Harjola, Veli Pekka

AU - Heymans, Stephane

AU - Hill, Loreena

AU - Lainscak, Mitja

AU - Lam, Carolyn S.P.

AU - Lund, Lars H.

AU - Lyon, Alexander R.

AU - Mebazaa, Alexandre

AU - Mueller, Christian

AU - Paulus, Walter J.

AU - Pieske, Burkert

AU - Piepoli, Massimo F.

AU - Ruschitzka, Frank

AU - Rutten, Frans H.

AU - Seferovic, Petar M.

AU - Solomon, Scott D.

AU - Shah, Sanjiv J.

AU - Triposkiadis, Filippos

AU - Wachter, Rolf

AU - Tschöpe, Carsten

AU - de Boer, Rudolf A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.

AB - There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.

KW - Biomarkers

KW - Heart failure

KW - Heart failure with preserved ejection fraction

KW - Pulmonary hypertension

KW - Right ventricular function

UR - http://www.scopus.com/inward/record.url?scp=85041471654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041471654&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1029

DO - 10.1002/ejhf.1029

M3 - Article

C2 - 29044932

AN - SCOPUS:85041471654

VL - 20

SP - 16

EP - 37

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -